Drug Profile
Research programme: TRAIL receptor agonists - Ligand Pharmaceuticals
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Crystal Bioscience
- Developer Ligand Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA
- 27 Jul 2016 Research programme: TRAIL receptor agonists - Crystal Bioscience is available for licensing as of 27 Jul 2016. http://www.crystalbioscience.com/
- 27 Jul 2016 Early research in Cancer in USA (unspecified route)